Growth Differentiation Factor 15 and Matrix Metalloproteinase 3 in Plasma as Biomarkers for Neuropathy and Nephropathy in Type 1 Diabetes.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE
    • Publication Information:
      Original Publication: Basel, Switzerland : MDPI, [2000-
    • Subject Terms:
      Diabetes Mellitus, Type 1*/complications ; Diabetes Mellitus, Type 1*/blood ; Growth Differentiation Factor 15*/blood ; Biomarkers*/blood ; Matrix Metalloproteinase 3*/blood ; Diabetic Neuropathies*/blood ; Diabetic Neuropathies*/diagnosis ; Diabetic Neuropathies*/etiology ; Diabetic Nephropathies*/blood ; Diabetic Nephropathies*/diagnosis; Humans ; Male ; Female ; Adult ; Case-Control Studies ; Middle Aged
    • Abstract:
      Diabetic neuropathy and nephropathy are common complications of type 1 diabetes (T1D). The symptoms are often elusive in the early stages, and available diagnostic methods can be improved using biomarkers. Matrix metalloproteinase 3 (MMP-3) has been identified in the kidneys and is thought to be involved in diabetic nephropathy. Growth differentiation factor 15 (GDF-15) has been suggested to have positive effects in diabetes, but is otherwise associated with adverse effects such as cardiovascular risk, declined kidney function, and neurodegeneration. This study aims to investigate plasma MMP-3 and GDF-15 as systemic biomarkers for diabetic neuropathy and nephropathy in T1D. The study involves patients with childhood-onset T1D ( n = 48, age 38 ± 4 years) and a healthy control group ( n = 30, age 38 ± 5 years). Neurophysiology tests, evaluations of albuminuria, and measurements of routine biochemical markers were conducted. The neuropathy impairment assessment (NIA) scoring system, where factors such as loss of sensation and weakened reflexes are evaluated, was used to screen for symptoms of neuropathy. MMP-3 and GDF-15 concentrations were determined in heparinized plasma using ELISA kits. In total, 9 patients (19%) had albuminuria, and 25 (52%) had diabetic neuropathy. No significant differences were found in MMP-3 concentrations between the groups. GDF-15 levels were higher in T1D, with median and interquartile range (IQR) of 358 (242) pg/mL in T1D and 295 (59) in controls ( p < 0.001). In the merged patient group, a positive correlation was found between MMP-3 and plasma creatinine, a negative correlation was found between MMP-3 and estimated glomerular filtration rate (eGFR; rho = -0.358, p = 0.012), and there was a positive correlation between GDF-15 and NIA (rho = 0.723, p < 0.001) and high-sensitive C-reactive protein (rho = 0.395, p = 0.005). MMP-3 was increased in macroalbuminuria and correlated positively with NIA only in the nine T1D patients with albuminuria (rho = 0.836, p = 0.005). The present study indicates that high MMP-3 is associated with low eGFR, high plasma creatinine, and macroalbuminuria, and that GDF-15 can be a biomarker for diabetic neuropathy in T1D. MMP-3 may be useful as biomarker for neuropathy in T1D with albuminuria.
    • References:
      Int J Mol Sci. 2021 Feb 25;22(5):. (PMID: 33669048)
      Diabetes Care. 2013 Oct;36(10):3187-94. (PMID: 23723354)
      J Clin Med. 2022 May 27;11(11):. (PMID: 35683420)
      Int J Mol Sci. 2023 Jun 26;24(13):. (PMID: 37445827)
      Diabetes. 2004 Oct;53(10):2569-73. (PMID: 15448085)
      Crit Rev Clin Lab Sci. 2019 Aug;56(5):333-350. (PMID: 31076013)
      Endocr Connect. 2022 Jul 12;11(7):. (PMID: 35700236)
      Diabetes Metab J. 2023 Nov;47(6):743-756. (PMID: 37670573)
      Cytokine Growth Factor Rev. 2021 Feb;57:11-18. (PMID: 33317942)
      Diab Vasc Dis Res. 2021 Mar-Apr;18(2):14791641211002470. (PMID: 33775157)
      Hormones (Athens). 2022 Dec;21(4):719-728. (PMID: 36280643)
      Sci Rep. 2021 Mar 4;11(1):5132. (PMID: 33664330)
      Cardiovasc Diabetol. 2015 Mar 10;14:31. (PMID: 25848912)
      Sci Rep. 2023 Aug 2;13(1):12508. (PMID: 37532799)
      Eur J Intern Med. 2023 Apr;110:77-85. (PMID: 36740468)
      Clin Exp Immunol. 2015 Nov;182(2):213-9. (PMID: 26206176)
      Elife. 2022 Aug 02;11:. (PMID: 35916366)
      J Clin Med. 2020 Jan 10;9(1):. (PMID: 31936869)
      Can J Diabetes. 2023 Mar;47(2):117-123.e7. (PMID: 36526573)
      Diabetes Care. 2010 Jul;33(7):1567-72. (PMID: 20357380)
      Diabetologia. 2019 Jan;62(1):78-86. (PMID: 30350239)
      J Diabetes Complications. 2023 Dec;37(12):108635. (PMID: 37989066)
      Clin Chim Acta. 2024 Jan 15;553:117725. (PMID: 38128817)
      Gene. 2018 Oct 5;673:22-31. (PMID: 29883760)
      Diabetes Care. 2010 Oct;33(10):2285-93. (PMID: 20876709)
      Geroscience. 2022 Apr;44(2):867-880. (PMID: 33961185)
      J Diabetes Complications. 2017 Sep;31(9):1376-1383. (PMID: 28711195)
      J Inflamm Res. 2024 May 09;17:2861-2871. (PMID: 38741613)
      Diabetes Care. 2012 Nov;35(11):2340-6. (PMID: 22815297)
      J Pers Med. 2021 Mar 22;11(3):. (PMID: 33810048)
      Brain Behav. 2022 Feb;12(2):e2502. (PMID: 35068064)
    • Contributed Indexing:
      Keywords: biomarkers; diabetic nephropathy; diabetic neuropathy; enzyme-linked immunosorbent assay; glomerular filtration rate; growth differentiation factor 15; high-sensitivity c-reactive protein; matrix metalloproteinase 3; plasma; type 1 diabetes mellitus
    • Accession Number:
      0 (Growth Differentiation Factor 15)
      0 (Biomarkers)
      EC 3.4.24.17 (Matrix Metalloproteinase 3)
      0 (GDF15 protein, human)
      EC 3.4.24.17 (MMP3 protein, human)
    • Publication Date:
      Date Created: 20240713 Date Completed: 20240713 Latest Revision: 20240718
    • Publication Date:
      20240718
    • Accession Number:
      PMC11242093
    • Accession Number:
      10.3390/ijms25137328
    • Accession Number:
      39000435